Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
How to use stock turnover to improve your investing
⏸️ Investing
Are these the 2 best long-term healthcare buys?
⏸️ Investing
Should you steer clear of these 16 heavily shorted stocks?
⏸️ Investing
Should you buy the ASX's top 4 healthcare stocks?
⏸️ Investing
Should you avoid these heavily shorted sectors and companies?
⏸️ Investing
Why you should buy Cochlear Limited
⏸️ Investing
2 companies that could see a share price turnaround
⏸️ Investing
Should you buy these 3 blue-chip beauties?
⏸️ Investing
Your ready to go, instant 6-share balanced portfolio
⏸️ Investing
Build your own family dynasty with these 4 wealth creators
⏸️ Investing
4 reasons why playing Monopoly can help your investing
⏸️ Investing
Is Cochlear Limited's new hybrid device a turning point?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
